NuCana is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by applying its ProTide technology to transform some of the prescribed chemotherapy agents, nucleoside analogs, into medicines. Utilizing its proprietary technology, Co. is developing new medicines, ProTides, designed to overcome main cancer resistance mechanisms and generate concentrations of anti-cancer metabolites in cancer cells. Co.'s ProTide candidates, Acelarin® and NUC-3373, are chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two chemotherapy agents. Co. is evaluating NUC-7738 in clinical trial for patients with solid tumors. The NCNA stock yearly return is shown above.
The yearly return on the NCNA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NCNA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|